Compass Pathways PLC banner

Compass Pathways PLC
NASDAQ:CMPS

Watchlist Manager
Compass Pathways PLC Logo
Compass Pathways PLC
NASDAQ:CMPS
Watchlist
Price: 9.41 USD 7.54%
Market Cap: $903.5m

Compass Pathways PLC
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Compass Pathways PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Compass Pathways PLC
NASDAQ:CMPS
Income from Continuing Operations
-$287.9m
CAGR 3-Years
-47%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income from Continuing Operations
-$219m
CAGR 3-Years
-25%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income from Continuing Operations
-£35.5m
CAGR 3-Years
5%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income from Continuing Operations
£47.7m
CAGR 3-Years
17%
CAGR 5-Years
3%
CAGR 10-Years
4%
Oxford BioMedica PLC
LSE:OXB
Income from Continuing Operations
-£30.6m
CAGR 3-Years
12%
CAGR 5-Years
-37%
CAGR 10-Years
-9%
Niox Group PLC
LSE:NIOX
Income from Continuing Operations
£7m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Compass Pathways PLC
Glance View

Market Cap
903.5m USD
Industry
Biotechnology

Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

CMPS Intrinsic Value
3.72 USD
Overvaluation 60%
Intrinsic Value
Price $9.41

See Also

What is Compass Pathways PLC's Income from Continuing Operations?
Income from Continuing Operations
-287.9m USD

Based on the financial report for Dec 31, 2025, Compass Pathways PLC's Income from Continuing Operations amounts to -287.9m USD.

What is Compass Pathways PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-37%

Over the last year, the Income from Continuing Operations growth was -86%. The average annual Income from Continuing Operations growth rates for Compass Pathways PLC have been -47% over the past three years , -37% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett